<DOC>
	<DOCNO>NCT02917187</DOCNO>
	<brief_summary>The primary objective study investigate efficacy repeat oral dose BIIB074 paroxysmal pain participant Primary Inherited Erythromelalgia ( EM ) . The secondary objective study investigate efficacy repeat oral dose BIIB074 vary additional aspect pain participant EM ; investigate safety tolerability repeat oral dose BIIB074 participant EM .</brief_summary>
	<brief_title>A Phase 2a Study BIIB074 Treatment Erythromelalgia</brief_title>
	<detailed_description>Convergence Pharmaceuticals , Ltd. , register England , acquire affiliate subsidiary Biogen , Inc .</detailed_description>
	<mesh_term>Erythromelalgia</mesh_term>
	<criteria>Key A diagnosis primary inherit EM family history EM make least 3 month initial diagnosis . Failed least one prior treatment EM ( define inadequate response intolerance treatment ) . Approved concomitant medication must stable least 4 week prior day 1 . Key Positive screen Hepatitis B surface antigen positive Hepatitis C antibody result . Received nerve block and/or steroid injection neuropathic pain within 4 week prior Day 1 . Males whose partner pregnant . Failed least one prior treatment EM ( define inadequate response intolerance treatment ) . NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>